<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="editorial" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id>
<journal-title>Frontiers in Endocrinology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Endocrinol.</abbrev-journal-title>
<issn pub-type="epub">1664-2392</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fendo.2023.1251148</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Endocrinology</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Myriad types of cell death in nephropathy and their veiled potential</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wada</surname>
<given-names>Jun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/289551"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tupe</surname>
<given-names>Rashmi S.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1303337"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sharma</surname>
<given-names>Isha</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/731359"/>
</contrib>
</contrib-group>    <aff id="aff1">
<sup>1</sup>
<institution>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University, Faculty of Medicine, Dentistry and Pharmaceutical Sciences</institution>, <addr-line>Okayama</addr-line>, <country>Japan</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Symbiosis School of Biological Sciences (SSBS), Symbiosis International (Deemed University) (SIU)</institution>, <addr-line>Pune, Maharashtra</addr-line>, <country>India</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Medicine, Feinberg School of Medicine, Northwestern University</institution>, <addr-line>Chicago, IL</addr-line>, <country>United States</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited and Reviewed by: Berthold Hocher, Heidelberg University, Germany</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Jun Wada, <email xlink:href="mailto:junwada@okayama-u.ac.jp">junwada@okayama-u.ac.jp</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>21</day>
<month>07</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1251148</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>06</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>07</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Wada, Tupe and Sharma</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Wada, Tupe and Sharma</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" xlink:href="https://www.frontiersin.org/research-topics/36215" ext-link-type="uri">Editorial on the Research Topic <article-title>Myriad types of cell death in nephropathy and their veiled potential</article-title>
</related-article>
<kwd-group>
<kwd>apoptosis</kwd>
<kwd>necroptosis</kwd>
<kwd>pyroptosis</kwd>
<kwd>ferroptosis</kwd>
<kwd>regulated cell death</kwd>
<kwd>chronic kidney disease</kwd>
<kwd>diabetic nephropathy</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="0"/>
<page-count count="2"/>
<word-count count="536"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Renal Endocrinology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>In the two main forms of cell death, necrosis is characterized by disruption of the plasma membrane, release of intracellular contents, and subsequent immunogenic and inflammatory processes, while apoptosis is a regulated cell death in which dying cells with preserved plasma membrane integrity are rapidly engulfed by phagocytes and orderly cleared without promotion of inflammation. Although necrosis is an accidental cell death, several forms of regulated necrosis, such as necroptosis, pyroptosis, ferroptosis, mitochondrial permeability transition-regulated necrosis (MPT-RN), autosis, and NETosis (neutrophil extracellular traps; NETs), are controlled by specific molecular machinery and programs, which are modulated by their corresponding inhibitor.</p>
<p>Necroptosis is triggered by various stimuli including the activation of death receptors (FAS and TNFRSF1A) and toll-like receptors. Subsequently, the receptor-interacting serine/threonine kinase 3 (RIPK3) is activated, which further activates mixed lineage kinase domain-like pseudokinase (MLKL) and induces membrane rupture.</p>
<p>Pyroptosis is initiated by pathogen-associated molecular pattern molecules (PAMPs) and damage-associated molecular patterns (DAMPs), activation of caspase 1 (CASP1) or CASP11, which cleaves gasdermin D (GSDMD) to produce a 22-kDa C-terminal (GSDMD-C) and a 31-kDa N-terminal fragment (GSDMD-N). Finally, GSDMD-N induces plasma membrane rupture and pyroptosis.</p>
<p>Ferroptosis is induced by iron-accumulation-induced reactive oxygen species (ROS) production and impaired antioxidants system against lipid peroxidation. In the former, lipid oxidation pathway involving acyl-CoA synthetase long-chain family member 4 (ACSL4), lysophosphatidylcholine acyltransferase 3 (LPCAT3), and arachidonate lipoxygenases 15 (ALOX15) is required for lipid oxidation in ferroptosis. In addition, the reduction in protective system including solute carrier family 7 member 11 (SLC7A11), phospholipid hydroperoxidase glutathione peroxidase 4 (GPX4), and transcription factor nuclear factor, erythroid 2 like 2 (NFE2L2, also known as NRF2) is also involved.</p>
<p>In this Research Topic, two review articles focus on diabetic nephropathy. Recently, the concept of &#x201c;diabetic tubulopathy&#x201d; has emerged, and &#x201c;tubulocentric theory&#x201d; arouses the broad attention, since SGLT2 inhibitors demonstrate the significant therapeutic potential against the progression of diabetic nephropathy. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fendo.2022.924299">Shen et&#xa0;al.</ext-link> summarize the cellular senescence and regulated cell death (apoptosis, autophagic cell death, necroptosis, pyroptosis, and ferroptosis) in tubular epithelial cells induced by high glucose, lipotoxicity, oxidative stress, and inflammation. Lipid metabolism disorder is a key factor in progression of diabetic nephropathy. Ectopic lipid deposition is aggravated in DN, which further promotes tubule cell inflammation and apoptosis and ultimately aggravates the pathological changes of diabetic nephropathy. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fendo.2022.1017387">Yang et&#xa0;al.</ext-link> sheds light on lipid droplets (LDs) connected to a part of the mitochondria known as the peridroplet mitochondria (PDM). <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fendo.2022.1017387">Yang et&#xa0;al.</ext-link> summarize the function of PDM and discuss the possibility of the use of PDM as a therapeutic target.</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fendo.2023.1085605">Zhang et&#xa0;al.</ext-link> discuss about the renal fibrosis, a common feature in the progression of chronic kidney disease (CKD). In recent years, cellular senescence of renal tubular epithelial cells can accelerate the progression of renal fibrosis. To eliminate the senescent cells, calorie restriction and routine exercise, Klotho, senolytics, and senostatics are postulated as interventions. The relation of apoptosis and ferroptosis in the pathogenesis of cellular senescence and renal fibrosis is also discussed.</p>
<sec id="s1" sec-type="author-contributions">
<title>Author contributions</title>
<p>JW drafted the editorial. All authors contributed to editing the manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
</body>
<back>
<sec id="s2" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s3" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</back>
</article>